NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free CPRX Stock Alerts $16.08 +0.01 (+0.06%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$15.75▼$16.3950-Day Range$13.18▼$17.0152-Week Range$11.09▼$18.22Volume1.30 million shsAverage Volume1.57 million shsMarket Capitalization$1.90 billionP/E Ratio26.36Dividend YieldN/APrice Target$26.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Catalyst Pharmaceuticals alerts: Email Address Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside65.2% Upside$26.57 Price TargetShort InterestBearish6.48% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment0.52Based on 22 Articles This WeekInsider TradingN/AProj. Earnings Growth34.83%From $1.78 to $2.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.95 out of 5 starsMedical Sector20th out of 947 stocksPharmaceutical Preparations Industry8th out of 435 stocks 4.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.57, Catalyst Pharmaceuticals has a forecasted upside of 65.2% from its current price of $16.08.Amount of Analyst CoverageCatalyst Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.48% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 14.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 2.5 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Catalyst Pharmaceuticals this week, compared to 5 articles on an average week.Search Interest19 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 73% compared to the previous 30 days.MarketBeat FollowsOnly 10 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.10% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.27% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 34.83% in the coming year, from $1.78 to $2.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 26.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 152.03.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 26.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 223.39.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 1.00. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm Press8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: Click to get the name of the cryptocurrency About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceMarch 16, 2024 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Gap Up to $16.62March 18, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 15, 2024 | finance.yahoo.comCPRX Apr 2024 12.500 callMarch 15, 2024 | finance.yahoo.comCPRX Apr 2024 17.500 putMarch 15, 2024 | americanbankingnews.comCitigroup Begins Coverage on Catalyst Pharmaceuticals (NASDAQ:CPRX)March 14, 2024 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: REPRO-MED Systems (KRMD), Catalyst Pharma (CPRX)March 14, 2024 | finance.yahoo.comCPRX Apr 2024 20.000 putMarch 18, 2024 | Porter & Company (Ad)My next big prediction isn’t a predictionI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.March 14, 2024 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United StatesMarch 14, 2024 | finance.yahoo.comSanthera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United StatesMarch 14, 2024 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Downgraded to "Hold" at StockNews.comMarch 14, 2024 | globenewswire.comSanthera's Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United StatesMarch 13, 2024 | markets.businessinsider.comCatalyst Pharmaceutical Gains Following US Commercial Launch Of AgamreeMarch 13, 2024 | globenewswire.comCatalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)March 10, 2024 | investorplace.com3 Sexy Small-Cap Stocks to Add Sizzle to Your PortfolioMarch 10, 2024 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives $27.20 Average Price Target from AnalystsMarch 9, 2024 | americanbankingnews.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Research Coverage Started at Bank of AmericaMarch 8, 2024 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. to Post FY2024 Earnings of $0.97 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CPRX)March 5, 2024 | fool.com3 Biopharma Stocks You Don't Want to Miss in the New Bull MarketMarch 5, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare ConferenceMarch 2, 2024 | seekingalpha.comCatalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comCatalyst: Q4 Earnings SnapshotFebruary 28, 2024 | msn.comCatalyst Pharmaceuticals Non-GAAP EPS of $0.53 beats by $0.07, revenue of $110.57M beats by $4.65MFebruary 28, 2024 | globenewswire.comCatalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 27, 2024 | markets.businessinsider.comHere's what Wall Street expects from Catalyst Pharmaceutical Partners's earningsSee More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/18/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees167Year Founded2002Price Target and Rating Average Stock Price Target$26.57 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+62.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$0.61 Trailing P/E Ratio26.74 Forward P/E Ratio9.16 P/E Growth1.02Net Income$71.41 million Net Margins17.93% Pretax Margin23.73% Return on Equity26.56% Return on Assets22.13% Debt Debt-to-Equity RatioN/A Current Ratio2.88 Quick Ratio2.68 Sales & Book Value Annual Sales$398.20 million Price / Sales4.83 Cash Flow$2.02 per share Price / Cash Flow8.08 Book Value$3.30 per share Price / Book4.94Miscellaneous Outstanding Shares117,863,000Free Float103,602,000Market Cap$1.92 billion OptionableOptionable Beta0.92 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Patrick J. McEnany (Age 77)Co-Founder & Chairman Comp: $1.2MMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Comp: $63.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Comp: $809.03kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Comp: $751.85kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Comp: $711.7kMr. Michael W. Kalb CPA (Age 53)Executive VP & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryMore ExecutivesKey CompetitorsSchrödingerNASDAQ:SDGRZai LabNASDAQ:ZLABMaravai LifeSciencesNASDAQ:MRVIArdelyxNASDAQ:ARDXAvidity BiosciencesNASDAQ:RNAView All CompetitorsInsiders & InstitutionsPVG Asset Management CorpBought 17,595 shares on 3/12/2024Ownership: 0.015%Vanguard Group Inc.Bought 73,930 shares on 3/11/2024Ownership: 6.041%Goldman Sachs Group Inc.Sold 9,906 shares on 3/1/2024Ownership: 0.815%Cim LLCBought 27,163 shares on 2/23/2024Ownership: 0.023%Price T Rowe Associates Inc. MDBought 18,390 shares on 2/16/2024Ownership: 1.018%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Catalyst Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CPRX shares. View CPRX analyst ratings or view top-rated stocks. What is Catalyst Pharmaceuticals' stock price target for 2024? 5 analysts have issued 1-year price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $23.00 to $34.00. On average, they expect the company's share price to reach $26.57 in the next year. This suggests a possible upside of 65.2% from the stock's current price. View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts. How have CPRX shares performed in 2024? Catalyst Pharmaceuticals' stock was trading at $16.81 at the start of the year. Since then, CPRX stock has decreased by 4.3% and is now trading at $16.08. View the best growth stocks for 2024 here. Are investors shorting Catalyst Pharmaceuticals? Catalyst Pharmaceuticals saw a increase in short interest during the month of February. As of February 29th, there was short interest totaling 6,470,000 shares, an increase of 14.1% from the February 14th total of 5,670,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 4.3 days. Currently, 6.5% of the company's shares are short sold. View Catalyst Pharmaceuticals' Short Interest. When is Catalyst Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CPRX earnings forecast. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.10. The biopharmaceutical company had revenue of $35.95 million for the quarter, compared to analyst estimates of $34.47 million. Catalyst Pharmaceuticals had a net margin of 17.93% and a trailing twelve-month return on equity of 26.56%. During the same period last year, the firm earned $0.11 earnings per share. What ETFs hold Catalyst Pharmaceuticals' stock? ETFs with the largest weight of Catalyst Pharmaceuticals (NASDAQ:CPRX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Biotechnology & Genome ETF (PBE), Janus Henderson Small Cap Growth Alpha ETF (JSML), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap Health Care ETF (PSCH), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and ALPS Medical Breakthroughs ETF (SBIO). What guidance has Catalyst Pharmaceuticals issued on next quarter's earnings? Catalyst Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $455.0 million-$475.0 million, compared to the consensus revenue estimate of $463.2 million. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD). Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.06%), Vanguard Group Inc. (6.04%), Dimensional Fund Advisors LP (2.21%), Boston Partners (1.31%), Northern Trust Corp (1.21%) and Opaleye Management Inc. (1.07%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CPRX) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThe world’s greatest investmentPorter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.